Impacts of ainuovirine-based and efavirenz-based antiretroviral therapies on the lipid profile of HIV/AIDS patients in southern China: a real-world study.

Journal: Frontiers in medicine
Published Date: Jan 8, 2024

Abstract

BACKGROUND: The newly approved third-generation oral anti-HIV-1 drug, ainuovirine (ANV), was used in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in our study, and its effects on the lipid profile of antiretroviral-experienced HIV/AIDS patients are unclear.

Authors

  • Quan Zhang
    Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Zhong Chen
    Institute of HIV/AIDS The First Hospital of Changsha, Changsha, China.
  • Yating Wang
    Graduate Collaborative Training Base of the First Hospital of Changsha, Hengyang Medical School, University of South China, Hengyang, China.
  • Yongquan Peng
    Graduate Collaborative Training Base of the First Hospital of Changsha, Hengyang Medical School, University of South China, Hengyang, China.
  • Si Tan
    Institute of HIV/AIDS The First Hospital of Changsha, Changsha, China.
  • Ying Li
    School of Information Engineering, Chang'an University, Xi'an 710010, China.
  • Guiying Cao
    Institute of HIV/AIDS The First Hospital of Changsha, Changsha, China.
  • Antonia Bignotti
    Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS, United States.
  • Shangjie Wu
    Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Min Wang
    National and Local Joint Engineering Research Center of Ecological Treatment Technology for Urban Water Pollution, Wenzhou University, Wenzhou 325035, China.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals